Related Experiment Video
Updated: Aug 18, 2026

Determination of Tolerable Fatty Acids and Cholera Toxin Concentrations Using Human Intestinal Epithelial Cells and BALB/c Mouse Macrophages
Published on: May 30, 2013
Fish oil reduces gastric acid secretion
C Riber1, M Wøjdemann, T Bisgaard
1Dept of Surgical Gastroenterology C, Rigshospitalet, University of Copenhagen, Denmark.
Background:
The aim of the present investigation was to study gastric acid secretion and release of gastrin, cholecystokinin (CCK), and secretin during intraduodenal perfusion of either fish oil or trioleate.
Methods:
Seven healthy volunteers were stimulated on two separate days in random order with intraduodenal perfusates of either fish oil or trioleate.
Results:
Intravenous infusion with gastrin-17 was used as a background stimulation in doses mimicking a postprandial situation (39.9 +/- 4.8 pmol/l fish oil and 43.6 +/- 3.8 pmol/l trioleate). Gastric acid secretion increased significantly from a basal level of 0.7 +/- 0.1 meq/15 min to 4.0 +/- 0.6 meq/15 min (P < 0.05) before perfusion of fish oil, which reduced gastric acid secretion to 1.9 +/- 0.4 meq/15 min (P < 0.01). After termination of fish oil perfusion gastric acid secretion increased to preperfusion concentrations (P < 0.01). Perfusion of trioleate did not influence gastric acid secretion. Plasma concentrations of CCK rose significantly during perfusion of fish oil (from 2.8 +/- 0.6 pmol/l to 4.4 +/- 0.7pmol/l, P<0.01), whereas trioleate only tended to increase CCK concentrations. Plasma concentrations of secretin did not change during perfusion of fish oil; however, concentrations were significantly lower during and after perfusion of trioleate (P < 0.01).
Conclusion:
The present study shows that intraduodenal perfusion of fish oil is associated with a significant reduction of the gastric acid secretion stimulated by gastrin in healthy humans.
More Related Videos
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

